Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of LS-301 eye drops for corneal epithelial injury
CTR20262391Phase 2Active
- Sponsor
- Guangdong Jida Gene Drug Engineering Research Center
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human acidic fibroblast growth factor in Corneal epithelial defect, dry eye syndrome (DED), sponsored by Guangdong Jida Gene Drug Engineering Research Center. Started Jun 2026; status: active.
02
Drugs
recombinant human acidic fibroblast growth factor
03
Conditions
Corneal epithelial defectdry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20262391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262391.